OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees

por Nilsson, C, Aboud, S, Karlén, K, Marovich, M, Wahren, B, Sandström, E, Gaines, H, Biberfeld, G, Godoy-Ramirez, K
Publicado 2009

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen

por Podola, L, Bauer, A, Haule, A, Sudi, L, Nilsson, C, Godoy-Ramirez, K, Mann, P, Missanga, M, Kaluwa, B, Maboko, L, Lueer, C, Mwakatima, M, Aboud, S, Bakari, M, Currier, J, Robb, M, McCormack, S, Joseph, S, Lyamuya, E, Hoelscher, M, Wahren, B, Sandström, E, Biberfeld, G, Geldmacher, C, Kroidl, A
Publicado 2012

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine

por Munseri, P, Kroidl, A, Nilsson, C, Moshiro, C, Aboud, S, Joachim, A, Geldmacher, C, Aris, E, Buma, D, Lyamuya, E, Gotch, F, Godoy-Ramirez, K, Pallangyo, K, Maboko, L, Marovich, M, Robb, M, Hoelscher, M, Janabi, M, Mann, P, Joseph, S, Mfinanga, S, Stoehr, W, Mhalu, F, Wahren, B, Biberfeld, G, McCormack, S, Sandstrom, E, Bakari, M
Publicado 2012